Neuroinflammation as a possible link between cannabinoids and addiction

Acta Neuropsychiatrica

Volumn 26, Issue 6, 2014, Pages 334-346

  Rodrigues, Livia C M ^a   Gobira, Pedro H ^b   De Oliveira, Antonio Carlos ^b   Pelição, Renan ^a   Teixeira, Antonio Lucio ^b   Moreira, Fabricio A ^b   Campos, Alline Cristina ^b  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

addiction; alcohol; cannabinoids; cocaine; neuroinflammation

Indexed keywords

ALCOHOL; CANNABINOID; CANNABIS; OPIATE; PSYCHOSTIMULANT AGENT; CANNABINOID 1 RECEPTOR;

ALCOHOLISM; CANNABIS ADDICTION; CLINICAL TRIAL (TOPIC); DRUG DEPENDENCE; HUMAN; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPIATE ADDICTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); TOBACCO DEPENDENCE; BEHAVIOR, ADDICTIVE; IMMUNOLOGY; METABOLISM; MICROGLIA; PATHOLOGY; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

BEHAVIOR, ADDICTIVE; CANNABINOIDS; HUMANS; MICROGLIA; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 84927518323     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2014.24     Document Type: Review

References (164)

1. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and statistical manual of mental disorders, text revision, 4th edn. Washington, DC: American Psychiatric Association, 2000.
2. KOOB GF, VOLKOW ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;1:217-238.
3. UNODOC. World Drug Report. United Nations Publications. New York, 2013; Sales E13.XI.6.
4. BLOOMFIELD MA, MORGAN CJ, EGERTON A, KAPUR S, CURRAN HV, HOWES OD. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2013;5:470-478.
5. IVERSEN L. Cannabis and the brain. Brain 2003;6:1252-1270.
6. MURRAY RM, MORRISON PD, HENQUET C, DI FORTI M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007;11:885-895.
7. WILEY JL. 1999 Cannabis: discrimination of 'internal bliss'? Pharmacol Biochem Behav 1999;64:257-260.
8. GARDNER EL, PAREDES W, SMITH D et al. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology 1988;96:142-144.
9. GARDNER EL, LOWINSON JH. Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav 1991;40:571-580.
10. CHEN JP, PAREDES W, LI J, SMITH D, LOWINSON J, GARDNER EL. Delta 9-tetrahydrocannabinol produces naloxoneblockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 1990;102:156-162.
11. XI ZX, GILBERT J, CAMPOS AC et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 2004;176: 57-65.
12. HILLARD CJ, BLOOM AS, HOUSLAY MD. Effects of delta 9- tetrahydrocannabinol on glucagon receptor coupling to adenylate cyclase in rat liver plasma membranes. Biochem Pharmacol 1986;35:2797-2803.
13. DEVANE WA, DYSARZ FA 3RD, JOHNSON MR, MELVIN LS, HOWLETT AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.
14. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
15. MECHOULAM R, HANUS L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000;108: 1-13.
16. FREUND TF, KATONA I, PIOMELLI D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003;83: 1017-1066.
17. KATONA I, FREUND TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008;14:923-930.
18. DI MARZO V, BIFULCO M, DE PETROCELLIS L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-784.
19. ONAIVI ES. An endocannabinoid hypothesis of drug reward and drug addiction. Ann N Y Acad Sci 2008;1139:412-421.
20. GARDNER EL, VOREL SR. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998;5:502-533.
21. SERRANO A, PARSONS LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 2011;132:215-241.
22. MALDONADO R, VALVERDE O, BERRENDERO F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006;29:225-232.
23. HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR, RICE KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1999;11:563-583.
24. UEDA N, GOPARAJU SK, KATAYAMA K, KURAHASHI Y, SUZUKI H, YAMAMOTO S. A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. J Med Invest 1998;45:27-36.
25. ATWOOD BK, MACKIE K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010;160:467-479.
26. HERMANN H, MARSICANO G, LUTZ B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002;109:451-460.
27. TANDA G, MUNZAR P, GOLDBERG SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000;3: 1073-1074.
28. ONAIVI ES. Commentary: functional neuronal CB2 cannabinoid receptors in the CNS. Curr Neuropharmacol 2011;9:205-208.
29. MANSBACH RS, NICHOLSON KL, MARTIN BR, BALSTER RL. Failure of delta(9)-tetrahydrocannabinol and CP 55, 940 to maintain intravenous self-administration under a fixedinterval schedule in rhesus monkeys. Behav Pharmacol 1994;5:219-225.
30. TANDA G, PONTIERI FE, DI CHIARA G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048-2050.
31. JUSTINOVA Z, SOLINAS M, TANDA G, REDHI GH, GOLDBERG SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously selfadministered by squirrel monkeys. J Neurosci 2005;25: 5645-5650.
32. JUSTINOVÁ Z, YASAR S, REDHI GH, GOLDBERG SR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci 2011;31:7043-7048.
33. TANDA G, GOLDBERG SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology 2003;169: 115-134.
34. JUSTINOVA Z, TANDA G, REDHI GH, GOLDBERG SR. Selfadministration of delta 9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 2003;169:135-140.
35. SOLINAS M, YASAR S, GOLDBERG SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 2007;56:393-405.
36. SCHLOSBURG JE, CARLSON BLA, RAMESH D et al. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 2009;11:342-352.
37. PAVA MJ, WOODWARD JJ. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol 2012;46:185-204.
38. COLOMBO G, ORRÙ A, LAI P et al. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 2007;36:102-112.
39. GONZALEZ S, FERNANDEZ-RUIZ J, SPARPAGLIONE V, PAROLARO D, RAMOS JA. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002;66:77-84.
40. CAILLE S, ALVAREZ-JAIMES L, POLIS I, STOUFFER DG, PARSONS LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 2007;27:3695-3702.
41. GONZALEZ S, VALENTI M, DE MIGUEL R et al. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol 2004;143:455-464.
42. BASAVARAJAPPA BS, YALAMANCHILI R, CRAVATT BF, COOPER TB, HUNGUND BL. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology 2006;50:834-844.
43. GALLATE JE, SAHAROV T, MALLET PE, MCGREGOR IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 1999;370:233-240.
44. HUNGUND BL, SZAKALL I, ADAM A, BASAVARAJAPPA BS, VADASZ C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003;84:698-704.
45. THANOS PK, DIMITRAKAKIS ES, RICE O, GIFFORD A, VOLKOW ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 2005;164:206-213.
46. SERRA S, CARAI MA, BRUNETTI G et al. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur J Pharmacol 2001;430:369-371.
47. GESSA GL, SERRA S, VACCA G, CARAI MA, COLOMBO G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol 2005;40:46-53.
48. SOYKA M, KOLLER G, SCHMIDT P et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, doubleblind trial. J Clin Psychopharmacol 2008;28:317-324.
49. GEORGE DT, HERION DW, JONES CL et al. Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology 2010;208:37-44.
50. ORTEGA-ÁLVARO A, TERNIANOV A, ARACIL-FERNÁNDEZ A, NAVARRETE F, GARCÍA-GUTIÉRREZ MS, MANZANARES J. Role of cannabinoid CB(2) receptor in the reinforcing actions of ethanol. Addict Biol 2013; doi:10.1111/adb.12076.
51. ARNOLD JC. The role of endocannabinoid transmission in cocaine addiction. Pharmacol Biochem Behav 2005;81: 396-406.
52. WISKERKE J, PATTIJ T, SCHOFFELMEER AN, DE VRIES TJ. The role of CB1 receptors in psychostimulant addiction. Addict Biol 2008;13:225-238.
53. DE VRIES TJ, SCHOFFELMEER AN. receptors control conditioned drug seeking. Trends Pharmacol Sci 2005;26:420-426.
54. FITZGERALD ML, SHOBIN E, PICKEL VM. Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:21-29.
55. SOLINAS M, JUSTINOVA Z, GOLDBERG SR, TANDA G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006;98:408-419.
56. SANCHIS-SEGURA C, SPANAGEL R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 2006;11:2-38.
57. CORBILLE AG, VALJENT E, MARSICANO G et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 2007;27:6937-6947.
58. FILIP M, GOLDA A, ZANIEWSKA M et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep 2006;58:806-819.
59. SORIA G, MENDIZABAL V, TOURINO C et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005;30:1670-1680.
60. XI ZX, SPILLER K, PAK AC et al. Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 2008;33:1735-1745.
61. VAUGHN LK, MANTSCH JR, VRANJKOVIC O et al. Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. Neuroscience 2012;204:117-124.
62. ALVARO-BARTOLOME M, GARCIA-SEVILLA JÁ. Dysregulation of cannabinoid CB receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents. Neuroscience 2013;247C:294-308.
63. ARACIL-FERNANDEZ A, TRIGO JM, GARCIA-GUTIERREZ MS et al. Decreased cocaine motor sensitization and selfadministration in mice overexpressing cannabinoid CB(2) receptors. Neuropsychopharmacology 2012;37:1749-1763.
64. XI ZX, PENG XQ, LI X et al. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci 2011;14:1160-1166.
65. CENTOZE D, BATTISTA N, ROSSI S et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic transmission. Neuropsychopharmacology 2004;29:1488-1497.
66. CALLIE S, ALVAREZ-JAIMES L, POLIS I, STOUFFER DG, PARSONS LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 2007;27:3695-3702.
67. JUSTINOVA Z, PANLILIO LV, GOLDBERG SR. Drug addiction. Curr Top Behav Neurosci 2009;1:309-346.
68. ADAMCZYK P, MCCREARY AC, PRZEGALINSKI E, MIERZEJEWSKI P, BIENKOWSKI P, FILIP M. The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J Physiol Pharmacol 2009;60:119-125.
69. VINKLEROVA J, NOVAKOVA J, SULCOVA A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251 J Psychopharmacol 2002;16: 139-143.
70. ANGGADIREDJA K, NAKAMICHI M, HIRANITA T et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 2004;29:1470-1478.
71. THIEMANN G, VAN DER STELT M, PETROSINO S, MOLLEMAN A, DI MARZO V, HASENOHRL RU. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamineinduced behavioural sensitization. Behav Brain Res 2008;187:289-296.
72. RUNKORG K, ORAV L, KOKS S, MATSUI T, VOLKE V, VASAR E. Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner. Behav Brain Res 2012;226: 335-339.
73. GUTIERREZ-LOPEZ MD, LLOPIS N, FENG S, BARRETT DA, O'SHEA E, COLADO MI. Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine. Br J Pharmacol 2010;160:772-783.
74. EISENSTEIN SA, HOLMES PV, HOHMANN AG. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Synapse 2009;63:941-950.
75. SCAVONE JL, STERLING RC, VAN BOCKSTAELE EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 2013;248:637-654.
76. TUCCI S. Addiction and pain: cannabinoid and opioid interactions. Curr Drug Targets 2010;11:392.
77. SOLINAS M, ZANGEN A, THIRIET N, GOLDBERG SR. Betaendorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur J Neurosci 2004;19:3183-3192.
78. CHAPERON F, SOUBRIE P, PUECH AJ, THIEBOT MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998;135:324-332.
79. NAVARRO M, CARRERA MR, FRATTA W et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001;21:5344-5350.
80. FATTORE L, SPANO MS, COSSU G, DEIANA S, FRATTA W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 2003;17:1723-1726.
81. COSSU G, LEDENT C, FATTORE L et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001;118:61-65.
82. LEDENT C, VALVERDE O, COSSU G et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283:401-404.
83. RAMESH D, HANEY M, COOPER ZD. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology 2013;38:1039-1049.
84. RABY WN, CARPENTER KM, ROTHENBERG J et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict 2009;18:301-308.
85. XI ZX, SPILLER K, GARDNER EL. Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin 2009;30:723-739.
86. PETERS EN, SCHWARTZ RP, WANG S, O'GRADY KE, BLANCO C. Psychiatric, psychosocial, and physical health correlates of co-occurring cannabis use disorders and nicotine dependence. Drug Alcohol Depend 2014;134:228-234.
87. VALJENT E, MITCHELL JM, BESSON MJ, CABOCHE J, MALDONADO R. Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 2002;135:564-578.
88. COHEN C, PERRAULT G, VOLTZ C, STEINBERG R, SOUBRIE P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002;13: 451-463.
89. FOLL LE, GOLDBERG B, RIMONABANT SR. A CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 2004;15:2139-2143.
90. COHEN C, KODAS E, GRIEBEL G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005;81:387-395.
91. CASTANE A. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002;43:857-867.
92. IGNATOWSKA-JANKOWSKA BM et al. The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology 2013;229:591-601.
93. GELFAND EV, CANNON CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006;15:307-315.
94. RIGOTTI NA, GONZALES D, DALE LC, LAWRENCE D, CHANG Y, GROUP CS. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 2009;104:266-276.
95. MULDOON PP, LICHTMAN AH, PARSONS LH, DAMAJ MI. The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. Life Sci 2013;92:458-462.
96. LUQUE-ROJAS MJ, GALEANO P, SUAREZ J et al. Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol 2013;16:661-676.
97. CLARK KH, WILEY CA, BRADBERRY CW. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 2013;23:174-188.
98. SADASIVAN S, POND BB, PANI AK, QU C, JIAO Y, SMEYNE RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 2012;7:e33693.
99. RAMAMOORTHY S, RAMAMOORTHY JD, PRASAD PD et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 1995;216:560-567.
100. ZALCMAN S, SAVINA I, WISE RA. Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res 1999;847:276-283.
101. ZALCMAN SS. Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. Brain Res 2001; 899:1-9.
102. HO BT, LU JG, HUO YY et al. Neurochemical basis of interleukin 2-modified discrimination behaviour. Cytokine 1994;6:365-367.
103. NAKAJIMA A, YAMADA K, NAGAI T et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 2004;24: 2212-2225.
104. YAMADA K, NABESHIMA T. Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction: mini review. Ann N Y Acad Sci 2004;1025:198-204.
105. GAN X, ZHANG L, NEWTON T et al. Cocaine infusion increases interferon-gamma and decreases interleukin-10 in cocaine-dependent subjects. Clin Immunol Immunopathol 1998;89:181-190.
106. AVILA AH, MORGAN CA, BAYER BM. Stress-induced suppression of the immune system after withdrawal from chronic cocaine. J Pharmacol Exp Ther 2003;305:290-297.
107. LLORENTE-GARCIA E, ABREU-GONZALEZ P, GONZALEZHERNANDEZ MC. Hematological, immunological and neurochemical effects of chronic amphetamine treatment in male rats. J Physiol Biochem 2009;65:61-69.
108. LEE YW, HENNIG B, YAO J, TOBOREK M. Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J Neurosci Res 2001;66:583-591.
109. BOGDAL J, CICHECKA K, KIRCHMAYER S, MIKA M, TARNAWSKI A. Immunoglobulins in chronic alcoholics: relation to liver histology and effect of 2-month abstinence therapy. Arch Immunol Ther Exp 1976;24:799-805.
110. REDWINE L, DANG J, HALL M, IRWIN M. Disordered sleep, nocturnal cytokines, and immunity in alcoholics. Psychosom Med 2003;65:75-85.
111. BLANK SE, DUNCAN DA, MEADOWS GG. Suppression of natural killer cell activity by ethanol consumption and food restriction. Alcohol Clin Exp Res 1991;15:16-22.
112. COHEN PR, HEBERT AA, ADLER-STORTHZ K. Focal epithelial hyperplasia: Heck disease. Pediatr Dermatol 1993;10: 245-251.
113. SCHLEIFER SJ, KELLER SE, CZAJA S. Major depression and immunity in alcohol-dependent persons. Brain Behav Immun 2006;20:80-91.
114. PETTINATI HM, O'BRIEN CP, DUNDON WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry 2013;170:23-30.
115. SZABO G, MANDREKAR P, PETRASEK J, CATALANO D. The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol Clin Exp Res 2011;35:782-786.
116. KHORUTS A, STAHNKE L, MCCLAIN CJ, LOGAN G, ALLEN JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-276.
117. NICOLAOU C, CHATZIPANAGIOTOU S, TZIVOS D, TZAVELLAS EO, BOUFIDOU F, LIAPPAS IA. Serum cytokine concentrations in alcohol-dependent individuals without liver disease. Alcohol 2004;32:243-247.
118. CHIVA-BLANCH G, URPI-SARDA M, LLORACH R et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. Am J Clin Nutr 2012;95:326-334.
119. COOK RT. Cytoplasmic cytokines in the T cells of chronic alcoholics. Alcohol Clin Exp Res 2000;24:241-243.
120. MANDREKAR P, BELLEROSE G, SZABO G. Inhibition of NF-kappa B binding correlates with increased nuclear glucocorticoid receptor levels in acute alcohol-treated human monocytes. Alcohol Clin Exp Res 2002;26:1872-1879.
121. ZHAO YN, WANG F, FAN YX, PING GF, YANG JY, WU CF. Activated microglia are implicated in cognitive deficits, neuronal death, and successful recovery following intermittent ethanol exposure. Behav Brain Res 2013; 236:270-282.
122. PASCUAL M, FERNANDEZ-LIZARBE S, GUERRI C. Role of TLR4 in ethanol effects on innate and adaptive immune responses in peritoneal macrophages. Immunol Cell Biol 2011; 89:716-727.
123. SZABO G, MANDREKAR P, OAK S, MAYERLE J. Effect of ethanol on inflammatory responses. Implications for pancreatitis. Pancreatology 2007;7:115-123.
124. FANG H, WANG PF, ZHOU Y, WANG YC, YANG QW. Toll-like receptor 4 signaling in intracerebral hemorrhageinduced inflammation and injury. J Neuroinflammation 2013;10:27.
125. AGRAWAL RG, HEWETSON A, GEORGE CM, SYAPIN PJ, BERGESON SE. Minocycline reduces ethanol drinking. Brain Behav Immun 2001;25(Suppl. 1):S165-S169.
126. HUTCHINSON MR, NORTHCUTT AL, CHAO LW et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 2008;22:1248-1256.
127. KOVACS KJ. Microglia and drug-induced plasticity in reward-related neuronal circuits. Front Mol Neurosci 2012;5:74.
128. THOMAS DM, FRANCESCUTTI-VERBEEM DM, KUHN DM. Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. Journal Neurochem 2008;106:696-705.
129. ESPINOSA-OLIVA AM, DE PABLOS RM, SARMIENTO M et al. Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures. Neurotoxicology 2014;41:89-101.
130. SHAH A, SILVERSTEIN PS, SINGH DP, KUMAR A. Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-kappaB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J Neuroinflammation 2012;9:52.
131. GALIEGUE S, MARY S, MARCHAND J, DUSSOSSOY D, CARRIERE D. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
132. KERR DM, HARHEN B, OKINE BN et al. The monoacylglycerol lipase inhibitor JZL184 attenuates LPSinduced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 2013;169:808-819.
133. KLEIN TW, FRIEDMAN H, SPECTER S. Marijuana, immunity and infection. J Neuroimmunol 1998;83:102-115.
134. KLEIN TW, NEWTON C, LARSEN K et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74:486-496.
135. ZHANG J, CHEN C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 2008;283:22601-22611.
136. SANCHO R, CALZADO MA, DI MARZO V, APPENDINO G, MUNOZ E. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol 2003;63:429-438.
137. NAVARRETE CM, FIEBICH BL, DE VINUESA AG et al. Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso- PGF formation in primary glial cells. J Neurochem 2009;109:452-464.
138. NOMURA DK, MORRISON BE, BLANKMAN JL et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011;334:809-813.
139. SHI J, JOHANSSON J, WOODLING NS, WANG Q, MONTINE TJ, ANDREASSON K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010;184:7207-7218.
140. CROXFORD JL, MILLER SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. J Clin Invest 2003;111:1231-1240.
141. ELJASCHEWITSCH E, WITTING A, MAWRIN C et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006;49:67-79.
142. MESTRE L, CORREA F, AREVALO-MARTIN A et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005;92:1327-1339.
143. ORTEGA-GUTIERREZ S. Therapeutic perspectives of inhibitors of endocannabinoid degradation. Curr Drug Targets CNS Neurol Disord 2005;4:697-707.
144. SUN Y, BENNET A. Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007;23513:49-55.
145. STAHEL PF, SMITH WR, BRUCHIS J, RABB CH. Peroxisome proliferator-activated receptors: 'key' regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008;2008:538141.
146. O'SULLIVAN S, BENNET A, KENDAL D, RANDALL M. Cannabinoids and peroxisome proliferator-activated receptor gamma (PPARγ). Proceedings of the International Cannabinoid Research Society (ICRS'06), Tihany, Hungary, 2006; 59.
147. ENAYATFARD L, ROSTAMI F, NASOOHI S, ORYAN S, AHMADIANI A, DARGAHI L. Dual role of PPAR-gamma in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55, 212-2. Neuromolecular Med 2013;15:523-535.
148. LIU PC, HUBER R, STOW MD et al. Induction of endogenous genes by peroxisome proliferator activated receptor alpha ligands in a human kidney cell line and in vivo. J Steroid Biochem Mol Biol 2003;85:71-79.
149. ROCKWELL CE, KAMINSKI NE. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 2004; 311:683-690.
150. ROCKWELL CE, SNIDER NT, THOMPSON JT, VANDEN HEUVEL JP, KAMINSKI NE. Interleukin-2 suppression by 2- arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 2006; 70:101-111.
151. COMBS CK, JOHONSON DE, KARLO JC, CANNADY SB, LANDRETH GE. Inflammatory mechanism in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatoryresponse and neurotoxicity by PPARγ. J Neurosci 2000;20:558-567.
152. COLINO M, ARAGNO M, MASTROCOLA R et al. Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia-reperfusion. Eur J Pharmacol 2006; 530:70-80.
153. ROCKWELL CE et al. Interleukin-2 supression by 2- arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 2006;70:101-111.
154. LE FOLL B, DI CIANO P, PANLILIO LV, GOLDBERG SR, CICCOCIOPPO R. Peroxisome proliferator-activated receptor (PPAR) agonsts as promising new medications for drug addiction: preclinical evidence. Curr Drug Targets 2013;14:768-776.
155. MATUTE C, ALBERDI E, IBARRETXE G, SANCHEZ-GOMEZ MV. Excitotoxicity in glial cells. Eur J Pharmacol 2002;447:239-246.
156. EHRHART J, OBREGON D, MORI T et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005;2:29.
157. ALBAYRAM O, ALFERINK J, PITSCH J et al. Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci U S A 2011;108:11256-11261.
158. MNICH SJ, HIEBSCH RR, HUFF RM, MUTHIAN S. Antiinflammatory properties of CB1-receptor antagonist involves beta2 adrenoceptors. J Pharmacol Exp Ther 2010;333:445-453.
159. CORREA F, MESTRE L, DOCAGNE F, GUAZA C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 2005;145:441-448.
160. ASHTON JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007;8:373-384.
161. MERIGHI S, GESSI S, VARANI K et al. Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. Br J Pharmacol 2012;165:1773-1788.
162. MORALES M, BONCI A. Getting to the ore of addiction: hooking CB2 receptor into drug abuse? Nat Med 2012;18:504-505.
163. MERIGHI S, GESSI S, VARANI K, FAZZI D, MIRANDOLA P, BOREA PA. Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. Br J Pharmacol 2012;166:2371-2385.
164. XI ZX, PENG XQ, LI X et al. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 2011;14:1100-1102.